Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
Source: financialcontent.com
Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinancialContent fully hosted finance channel
New real-world data “adds to the evidence that use of long-acting mAb [nirsevimab] may prevent moderate to severe RSV disease” in infants.
RSV is the most common cause of LRTD, including bronchiolitis and pneumonia, in infants.
A target action date for the FDA is expected in Q3 2023 and if greenlit, Sanofi’s nirsevimab would be the first broadly-approved RSV vaccine for children.